Evaluation of a new class of antimicrobial agents against Clostridium difficile

新型艰难梭菌抗菌药物的评价

• 批准号: 8337880
• 负责人: Terry L. Bowlin
• 金额: $ 89.79万
• 依托单位: TUFTS UNIVERSITY BOSTON
• 依托单位国家: 美国
• 财政年份: 2011
• 资助国家: 美国
• 起止时间: 2011-09-30 至 2013-09-29
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8337880
• 关键词: Acute; Affect; Anaerobic Bacteria; Animal Model; Animals; Anti-Bacterial Agents; Antibiotic Therapy; Antibiotics; Bacteria; Biological Availability; Cessation of life; Characteristics; Chemistry; Chronic; Clinic; Clinical; Clostridium difficile; DNA biosynthesis; DNA-Directed DNA Polymerase; Development; Diarrhea; Disease; Dose; Drug Formulations; Drug Kinetics; Elderly; Epidemic; Europe; Evaluation; Exhibits; Exotoxins; FDA approved; Fluoroquinolones; Frequencies; Goals; Hamsters; Hospitalization; Hospitals; Hybrids; In Vitro; Incidence; Infection; Inflammatory Bowel Diseases; Intervention; Intestines; Label; Laboratories; Large Intestine; Libraries; Mediating; Metronidazole; Modeling; Morbidity - disease rate; Mus; North America; Oral; Oral Administration; Patients; Pharmaceutical Preparations; Phase; Polymers; Precipitating Factors; Prevention; Probiotics; Pseudomembranous Colitis; Recurrence; Recurrent disease; Relapse; Request for Applications; Safety; Screening procedure; Solubility; Testing; Topoisomerase; Toxic effect; Toxicology; Toxin; Toxoids; Uracil; Vaccines; Vancomycin; Work; absorption; analog; antimicrobial drug; bactericide; capsule; drug administration duration; efficacy evaluation; factor C; fluoroquinolone resistance; inhibitor/antagonist; mortality; mouse model; novel therapeutic intervention; potency testing; pre-clinical; preclinical efficacy; preclinical evaluation; preclinical safety; prevent; prototype; resistant strain; response; treatment strategy